FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing

por Wang, Z, Dove, P, Wang, X, Shamas-Din, A, Li, Z, Nachman, A, Oh, Y J, Hurren, R, Ruschak, A, Climie, S, Press, B, Griffin, C, Undzys, E, Aman, A, Al-awar, R, Kay, L E, O'Neill, D, Trudel, S, Slassi, M, Schimmer, A D
Publicado 2015